Literature DB >> 19192112

Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage.

S L Haberichter1, A M Allmann, M A Jozwiak, R R Montgomery, J C Gill.   

Abstract

BACKGROUND: The large von Willebrand factor (VWF) propeptide (VWFpp) plays a critical role in the multimerization and regulated storage of the mature VWF protein. Although our laboratory and others have identified mutations in von Willebrand disease patients that disrupt VWF multimerization, little is known about the affect of mutations on the regulated storage of VWF. PATIENTS/
METHODS: We identified a heterozygous 18 base pair, in-frame deletion in exon 12 of the VWF gene in a patient with an unusual, dimer-intense multimer pattern. This deletion results in loss of amino acids 436-442 of VWFpp, which include one cysteine.
RESULTS: Through expression studies, we demonstrate reduced secretion, loss of VWF multimerization, and defective regulated storage of the variant VWF. The loss of VWF storage is secondary to loss of propeptide storage resulting from an apparently defective sorting signal on VWFpp. Suprisingly, coexpressed wild-type VWF or VWFpp functioned in trans to partially restore multimerization of VWF from the variant allele.
CONCLUSIONS: The deletion of six amino acids in VWFpp results in defects in VWF processing, regulated storage, and function. Although VWFpp may usually function in a homotypic fashion, acting on its own mature VWF subunit, VWFpp may retain the ability to function in trans on VWF expressed from the variant allele.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19192112      PMCID: PMC2745278          DOI: 10.1111/j.1538-7836.2009.03290.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  29 in total

1.  von Willebrand factor storage and multimerization: 2 independent intracellular processes.

Authors:  S L Haberichter; S A Fahs; R R Montgomery
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

2.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Authors:  Paula D James; Colleen Notley; Carol Hegadorn; Jayne Leggo; Angie Tuttle; Shawn Tinlin; Christine Brown; Chandler Andrews; Andrea Labelle; Yvette Chirinian; Lee O'Brien; Maha Othman; Georges Rivard; Dilys Rapson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

3.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

4.  Selective and signal-dependent recruitment of membrane proteins to secretory granules formed by heterologously expressed von Willebrand factor.

Authors:  Anastasia D Blagoveshchenskaya; Matthew J Hannah; Simon Allen; Daniel F Cutler
Journal:  Mol Biol Cell       Date:  2002-05       Impact factor: 4.138

Review 5.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

6.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

Authors:  Anne Goodeve; Jeroen Eikenboom; Giancarlo Castaman; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Reinhard Schneppenheim; Ulrich Budde; Jorgen Ingerslev; David Habart; Zdena Vorlova; Lars Holmberg; Stefan Lethagen; John Pasi; Frank Hill; Mohammad Hashemi Soteh; Luciano Baronciani; Christer Hallden; Andrea Guilliatt; Will Lester; Ian Peake
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

7.  A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion.

Authors:  S Allen; A M Abuzenadah; J Hinks; J L Blagg; T Gursel; J Ingerslev; A C Goodeve; I R Peake; M E Daly
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

8.  The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF.

Authors:  Jonathan B Rosenberg; Sandra L Haberichter; Mary A Jozwiak; Elizabeth A Vokac; Philip A Kroner; Scot A Fahs; Yohko Kawai; Robert R Montgomery
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

9.  Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor.

Authors:  Ren-Huai Huang; Ying Wang; Robyn Roth; Xiong Yu; Angie R Purvis; John E Heuser; Edward H Egelman; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-08       Impact factor: 11.205

10.  The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies.

Authors:  Grégoire Michaux; Kate B Abbitt; Lucy M Collinson; Sandra L Haberichter; Keith E Norman; Daniel F Cutler
Journal:  Dev Cell       Date:  2006-02       Impact factor: 12.270

View more
  11 in total

1.  The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Authors:  Sandra L Haberichter; Ulrich Budde; Tobias Obser; Sonja Schneppenheim; Cornelia Wermes; Reinhard Schneppenheim
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

Review 2.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

3.  Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

Authors:  Paula M Jacobi; Joan Cox Gill; Veronica H Flood; David A Jakab; Kenneth D Friedman; Sandra L Haberichter
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

4.  Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort.

Authors:  Marco Campos; Wei Sun; Fuli Yu; Maja Barbalic; Weihong Tang; Lloyd E Chambless; Kenneth K Wu; Christie Ballantyne; Aaron R Folsom; Eric Boerwinkle; Jing-Fei Dong
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

Review 5.  Functional architecture of Weibel-Palade bodies.

Authors:  Karine M Valentijn; J Evan Sadler; Jack A Valentijn; Jan Voorberg; Jeroen Eikenboom
Journal:  Blood       Date:  2011-01-25       Impact factor: 22.113

6.  Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF.

Authors:  Tara C White-Adams; Christopher J Ng; Paula M Jacobi; Sandra L Haberichter; Jorge A Di Paola
Journal:  Thromb Res       Date:  2016-08-10       Impact factor: 3.944

7.  von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion.

Authors:  Sri R Madabhushi; Chengwei Shang; Kannayakanahalli M Dayananda; Kate Rittenhouse-Olson; Mary Murphy; Thomas E Ryan; Robert R Montgomery; Sriram Neelamegham
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

8.  Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Authors:  A L Doruelo; S L Haberichter; P A Christopherson; L N Boggio; S Gupta; S R Lentz; A D Shapiro; R R Montgomery; V H Flood
Journal:  J Thromb Haemost       Date:  2017-06-23       Impact factor: 5.824

9.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

10.  Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.

Authors:  Nina Borràs; Javier Batlle; Almudena Pérez-Rodríguez; María Fernanda López-Fernández; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Ignacia Balda; Carme Altisent; Rocío Pérez-Montes; Rosa María Fisac; Gemma Iruín; Sonia Herrero; Inmaculada Soto; Beatriz de Rueda; Víctor Jiménez-Yuste; Nieves Alonso; Dolores Vilariño; Olga Arija; Rosa Campos; María José Paloma; Nuria Bermejo; Rubén Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Lizheidy Sarmiento; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Jesús María César; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Rosa Cornudella; Carlos Aguilar; Francisco Vidal; Irene Corrales
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.